Dashboard
Manage Tickers

TNXPTonix Pharmaceuticals Holdi...

Nasdaq tonixpharma.com


$ 0.18 $ 0.01 (5.2 %)    

Tuesday, 14-May-2024 15:59:20 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 450.52 $ 1.60 (0.36 %)
DIA $ 398.18 $ 0.29 (0.07 %)
SPY $ 528.01 $ 2.09 (0.4 %)
TLT $ 91.98 $ 0.14 (0.15 %)
GLD $ 220.23 $ 0.99 (0.45 %)
$ 0.18
$ 0.17
$ 0.00 x 0
$ 0.00 x 0
$ 0.17 - $ 0.19
$ 0.12 - $ 2.13
4,118,701
na
14.56M
$ -0.01
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 04-01-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-08-2023 03-31-2023 10-Q
6 03-13-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 03-14-2022 12-31-2021 10-K
11 11-08-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-15-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-24-2020 12-31-2019 10-K
19 11-08-2019 09-30-2019 10-Q
20 08-12-2019 06-30-2019 10-Q
21 05-13-2019 03-31-2019 10-Q
22 03-18-2019 12-31-2018 10-K
23 11-09-2018 09-30-2018 10-Q
24 08-13-2018 06-30-2018 10-Q
25 05-11-2018 03-31-2018 10-Q
26 03-09-2018 12-31-2017 10-K
27 11-06-2017 09-30-2017 10-Q
28 08-11-2017 06-30-2017 10-Q
29 05-12-2017 03-31-2017 10-Q
30 04-13-2017 12-31-2016 10-K
31 11-10-2016 09-30-2016 10-Q
32 08-05-2016 06-30-2016 10-Q
33 05-06-2016 03-31-2016 10-Q
34 03-03-2016 12-31-2015 10-K
35 11-06-2015 09-30-2015 10-Q
36 08-07-2015 06-30-2015 10-Q
37 05-08-2015 03-31-2015 10-Q
38 02-27-2015 12-31-2014 10-K
39 11-07-2014 09-30-2014 10-Q
40 08-08-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

tonix-pharmaceuticals-q1-2024-gaap-eps-018-beats-039-estimate-sales-2482m-miss-3800m-estimate
Tonix Pharmaceuticals Q1 2024 GAAP EPS $(0...
05/13/2024 20:42:12

Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of...

Core News & Articles
WHO's Tedros Adhanom Ghebreyesus Posts On ...
04/11/2024 14:09:23

https://twitter.com/DrTedros/status/1778423967105139108  

tonix-pharmaceuticals-q4-eps-086-beats-155-estimate-sales-380m-miss-575m-estimate
Tonix Pharmaceuticals Q4 EPS $(0.86) Beats...
04/01/2024 20:28:39

Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(0.86) per share which beat the analyst consensus estimate of...

tonix-pharmaceuticals-stock-tnxp-hits-a-new-all-time-low-whats-going-on
Tonix Pharmaceuticals Stock (TNXP) Hits A ...
04/01/2024 14:43:24

Tonix Pharmaceuticals shares are trading lower by 7.2% Monday. The company last week announced the pricing of a $4.4 million re...

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
03/29/2024 16:30:53

why-kodiak-sciences-shares-are-trading-lower-by-around-20-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Kodiak Sciences Shares Are Trading Low...
03/28/2024 18:08:52

Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-e...

why-tonix-pharmaceuticals-stock-tnxp-is-getting-obliterated
Why Tonix Pharmaceuticals Stock (TNXP) Is ...
03/28/2024 17:02:53

Tonix Pharmaceuticals shares are trading lower by 22.3% Thursday afternoon. The company announced the pricing of a $4.4 million...

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
03/28/2024 16:31:26

tonix-pharmaceuticals-prices-44m-registered-direct-offering-of-14666666-shares-and-warrants-at-030share-warrants-have-exercise-price-of-033share
Tonix Pharmaceuticals Prices $4.4M Registe...
03/28/2024 13:35:31

tonix-pharmaceuticals-receives-rare-pediatric-disease-designation-from-the-fda-for-tnx-2900-for-the-treatment-of-prader-willi-syndrome
Tonix Pharmaceuticals Receives Rare Pediat...
03/25/2024 12:06:31

TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces ...

tonix-pharmaceuticals-announces-poster-presentation-describing-discovery-of-novel-next-generation-oxytocin-analogues-at-the-american-chemistry-society-spring-2024-meeting
Tonix Pharmaceuticals Announces Poster Pre...
03/21/2024 12:07:10

Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, bi...

tonix-pharmaceuticals-announces-selection-of-two-contract-manufacturing-organizations-for-the-launch-and-commercial-manufacture-of-tonmya-for-management-of-fibromyalgia-nda-submission-planned-for-2h-of-2024
Tonix Pharmaceuticals Announces Selection ...
03/20/2024 12:04:34

tonix-pharmaceuticals-announces-transition-to-fully-integrated-biopharmaceutical-company-expected-on-april-1-2024
Tonix Pharmaceuticals Announces Transition...
03/19/2024 12:04:09

Zembrace® SymTouch® and Tosymra® will be marketed by Tonix Medicines, Tonix's wholly-owned commercial subsidiary Commercial...

tonix-pharmaceuticals-announces-phase-3-resilient-study-of-tonmya-met-its-primary-endpoint-of-daily-pain-reduction-and-achieved-statistically-significant-improvements-on-all-size-key-pre-speceified-secondary-endpoints
Tonix Pharmaceuticals Announces Phase 3 RE...
03/11/2024 12:02:45

tonix-pharmaceuticals-announces-publication-in-psychiatry-research-showing-activity-of-bedtime-tnx-102-sl-on-ptsd-symptoms-and-sleep-quality-in-military-related-ptsd-at-four-weeks-of-therapy
Tonix Pharmaceuticals Announces Publicatio...
03/07/2024 13:10:29

Data support evaluation of the effects of two weeks of TNX-102 SL therapy on severity of acute stress reaction (ASR) and freque...

tonix-pharmaceuticals-selects-eversana-to-support-launch-strategy-and-commercialization-planning-of-tonmya-for-the-management-of-fibromyalgia
Tonix Pharmaceuticals Selects EVERSANA To ...
03/06/2024 13:12:36

Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia, supported by st...

tonix-pharmaceuticals-announces-translation-of-preclinical-pharmacokinetic-parameters-of-tnx-1500-supports-monthly-iv-dosing-in-humans
Tonix Pharmaceuticals Announces Translatio...
03/05/2024 13:07:44

TNX-1500, a third generation anti-CD40L mAb, was Fc-modified to preserve the activity and bioavailability of first generation m...

dawson-james-initiates-coverage-on-tonix-pharmaceuticals-with-buy-rating-announces-price-target-of-3
Dawson James Initiates Coverage On Tonix P...
02/28/2024 19:50:45

Dawson James analyst Jason Kolbert initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy rating and announces...

tonix-pharmaceuticals-completes-clinical-stage-of-phase-1-trial-for-tnx-1500-in-healthy-volunteers
Tonix Pharmaceuticals Completes Clinical S...
02/28/2024 13:03:07

Topline results expected in the third quarter of 2024; planning a Phase 2 Trial for prevention of kidney transplant rejection A...

tonix-pharmaceuticals-announces-results-from-clinical-pharmacokinetic-bridging-study-of-tonmya-to-support-development-and-partnering-in-japan-and-china
Tonix Pharmaceuticals Announces Results Fr...
02/27/2024 13:07:46

Tonix plans to File a Clinical Trial Notification (CTN) in Japan and Investigational New Drug (IND) application in China to sup...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION